Dr. Deborah Siegal MD MSc FRCPC is a Hematologist (Thrombosis) at The Ottawa Hospital, an Associate Professor of Medicine at the University of Ottawa, and Scientist at the Ottawa Hospital Research Institute. She holds a Tier 2 Canada Research Chair in Anticoagulant Treatment of Cardiovascular Disease. She received MSc degrees in Pharmacology and Health Research Methodology.

As a clinician-scientist, Dr. Siegal combines her clinical and research expertise to conduct practice-changing research to improve the outcomes of individuals with cardiovascular disease, the most common non-communicable cause of morbidity and mortality worldwide. Her overall goal is to improve the safety of anticoagulant therapy, which is highly effective, but increases the risk of serious bleeding, the most common adverse drug event leading to emergency department visits, hospitalization, and death in North America.

Dr. Siegal’s research has had international, practice changing impact. She led clinical trials establishing the efficacy and safety of andexanet alfa, a novel anticoagulant reversal therapy for patients with serious bleeding, which ultimately led to its regulatory approval. She also led the STRATUS Trial which showed that a simple switch to tubes that automatically collect less blood for laboratory testing reduced the number of transfusions given in intensive care units.

She holds peer-reviewed grants as principal investigator from the Canadian Institutes of Health Research, CanVECTOR, Heart and Stroke Foundation of Canada, American Society of Hematology, and others. She has published over 160 peer-reviewed articles (h-index 45) including high-impact journals such the New England Journal of Medicine, JAMA, Circulation, Annals of Internal Medicine, Blood and Journal of Thrombosis and Haemostasis.

Dr. Siegal holds leadership roles within professional organizations in Canada (Thrombosis Canada, CanVECTOR) and internationally (International Society on Thrombosis and Haemostasis, American Society of Hematology, Hemostasis and Thrombosis Research Society) which is a testament to her commitment to collaboration.